Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.

N/ACompletedNCT00801437

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.457 enrolled

Overview

This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma

according to physicians decision, patients who met inclusion and exclusion criteria and sign the ICD

Study Type

OBSERVATIONAL

Enrollment

457

Conditions

Glaucoma, Open-angle

Interventions

XalacomDRUG

Xalacom 1 drop into the affected eye daily

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * primary open angle glaucoma * ocular hypertension * age \>18 years Exclusion Criteria: * bradycardia * obstructive pulmonary disease * hypersensitivity to the drug

Locations (39)

Outcomes

Primary Outcomes

Incidence of ocular hyperemia

Time frame: 12 months

safety of treatment

Time frame: 12 months

Secondary Outcomes

effectiveness in IOP lowering

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Banovce N. Bebravou, Slovakia

Pfizer Investigational Site

Banská Bystrica, Slovakia

Pfizer Investigational Site

Bojnice, Slovakia

Pfizer Investigational Site

Bratislava, Slovakia

Pfizer Investigational Site

Bratislava, Slovakia

Pfizer Investigational Site

Bratislava, Slovakia

Pfizer Investigational Site

Bratislava, Slovakia

Pfizer Investigational Site

Brezno, Slovakia

Pfizer Investigational Site

Dunajská Streda, Slovakia

Pfizer Investigational Site

Galanta, Slovakia

...and 29 more locations